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Leptin regulates appetite and body weight via hypothalamic
targets, but it can act directly on cultured pancreatic islets
to regulate their fat metabolism. To obtain in vivo evidence
that leptin may act peripherally as well as centrally, we
compared the effect of adenovirally induced hyperleptine-
mia on food intake, body weight, and islet fat content in
ventromedial hypothalamic-lesioned (VMHL) rats, sham-
lesioned (SL) controls, and Zucker Diabetic Fatty (ZDF)
rats in which the leptin receptor is mutated. Infusion with
recombinant adenovirus containing the rat leptin cDNA in-
 




 20 ng/ml in VMHL and ZDF
rats but had no effect on their food intake, body weight, or
fat tissue weight. Caloric matching of hyperphagic VMHL
rats to SL controls did not reduce their resistance to hyper-
leptinemia. Whereas prediabetic ZDF rats had a fourfold el-
evation in islet fat, in VMHL rats islet fat was normal and
none of them became diabetic. Isolated islets from ZDF rats
were completely resistant to the lipopenic action of leptin,
while VMHL islets exhibited 50% of the normal response;
caloric matching of VMHL rats to SL controls increased
leptin responsiveness of their islets to 92% of controls. We
conclude that leptin regulation of adipocyte fat requires an
intact VMH but that islet fat content is regulated indepen-
 




































The hypothalamus plays a crucial role in the control of food in-
take, thermogenesis, and body composition (1–8). The discov-
ery of leptin (3) and neuropeptide Y (NP-Y) (4) have ex-
panded our understanding of the mechanisms involved in
hypothalamic obesity. It has been established that the full-




 is preferentially ex-
pressed in the ventromedial hypothalamic (VMH) nucleus (5)
and that it downregulates the expression of the NP-Y gene,
which encodes an appetite-stimulating neuropeptide (6–8).








 mice (3), when OB-Rb is








 mice (9, 10), when all OB-R isoforms are








) Zucker Diabetic Fatty
(ZDF) rats (11, 12), or when the VMH nucleus is ablated (13),
hyperphagia and obesity ensue. However, the latter syndrome
differs from the three genetically determined syndromes in
that the loss of leptin action is presumably confined to the
ablated area and, unlike the genetic syndromes, should not
involve extrahypothalamic tissues that express the normal
OB-R. Furthermore, diabetes, which complicates all three of
the genetic forms of obesity, is reported not to occur in VMH-
lesioned (VMHL) animals (14).
Although an abundance of evidence points to leptin as the
principal signal to the hypothalamus for regulation of body
composition, leptin also has striking direct extraneural effects
on both adipocytes (15) and nonadipocytes (16, 17). For exam-
ple, it lowers the fat content of isolated islets by directly upreg-
ulating the mRNA of enzymes of fatty acid oxidation, car-
nitine palmitoyl transferase-1 (CPT-1) and acyl-CoA oxidase
(ACO), and downregulating mRNA of enzymes of lipogene-
sis, fatty acid synthetase, fatty acyl-CoA synthetase, and glyc-
erol-phosphate acyl transferase (18). There are also in vivo ob-
servations consistent with direct leptin action. For example,
when ectopic hyperleptinemia is induced by adenoviral trans-
fer of the leptin cDNA into normal lean rats, all visible fat tis-
sue disappears within 1 wk (19) and fat content falls dramati-
cally in nonadipocytes as well (20); the disappearance of fat is
accompanied by the same increase in expression of genes en-
coding enzymes of fatty acid oxidation, CPT-1 and ACO (19),
as was observed in vitro.
In an attempt to determine if the rapid generalized fat deple-
tion caused by ectopic hyperleptinemia is entirely mediated by
the VMH nucleus, we induced hyperleptinemia by adenoviral
leptin gene transfer in a group of VMHL rats. We had expected
that hyperphagia, which is clearly the result of the hypothalamic
lesion, would be resistant to the ectopic hyperleptinemia; how-
ever, given the presumed qualitative and quantitative integrity
of the extrahypothalamic leptin receptors, we expected that all
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OB-R–expressing peripheral tissues, including adipocytes,
would respond to the hyperleptinemia. This study was de-




VMHL and sham-lesioned controls.
 
This VMHL was performed at
the Department of Neuroscience, University of Florida (Gainesville,
FL) as approved by the University of Florida Institutional Animal
Care and Use Committee, which follows the National Institutes of
Health Guide for the Care and Use of Laboratory Animals. Adult
Sprague Dawley (HSD-HD; Harlan Sprague-Dawley, Indianapolis,





C) with lights on from 0500–1900 h. Food and water
were available ad libitum. Rats were weighed and anesthetized with
sodium pentobarbital (50 mg/kg i.p.; Abbott Laboratories, North
Chicago, IL). The VMH was destroyed bilaterally by the previously
described electrolytic lesion procedure (21). Briefly, rats were placed
in the stereotaxic instrument and positioned with the nose bar set
3.3 mm below the interaural line. The electrode, consisting of an insu-
lated stainless steel insect pin with exposed tip, was positioned 2.6 mm
behind the bregma, 0.6 mm lateral to the midline, and then lowered
to the base of the brain and then raised 0.5 mm. A direct anodal cur-
rent of 2.5 mA for 15 s was passed through the electrode aimed at the
VMH with a rectal electrode serving as a cathode. For sham-lesioning
(SL), the same surgical procedures were performed except that no
current was passed. Rats were allowed to recover for approximately 1













) ZDF-drt rats were bred in our lab-
oratory from [ZDF/Drt-fa(F10)] rats purchased from R. Peterson
(University of Indiana School of Medicine, Indianapolis, IN). 6- to








) rats were used in this study. All Sprague








) rats were studied in individual metabolic
cages (Nalgene, Rochester, NY), and body weight and food intake
were measured daily. Free-feeding rats were on standard chow
(model F6-8664; Teklad, Madison, WI) ad libitum and had free access
to water. Calorically matched rats received exactly the amount of




To induce hyperleptinemia in SL and
VMHL rats, recombinant adenovirus containing the rat leptin cDNA
(AdCMV-leptin) was prepared as previously described (19). Briefly,
a Bam HI– and Xba I–restricted leptin cDNA fragment that includes









was ligated to similarly treated pACCMVpLpA. The resulting plas-
mid was cotransfected with pJM17 into 293 cells by calcium phos-
phate/DNA coprecipitation to generate the AdCMV-leptin. Stocks of
AdCMV-leptin were amplified and purified as described (22), and








C in phosphate buffer solution with 0.2% bovine








 pfu/ml. A virus contain-









gal) was prepared and used as described previ-









 pfu was infused into the right cervical vein of uncon-





Blood samples were collected from the
tail vein in capillary tubes coated with ethylenediaminetetraacetic








C. Plasma leptin was assayed by ra-
dioimmunoassay using the Linco leptin assay kit (Linco Research, St.
Charles, MO), and insulin radioimmunoassay was performed as pre-
viously described (19). Plasma glucose was measured by the glucose
oxidase method using a glucose analyzer (glucose analyzer II, Beck-
man, Brea, CA). Plasma free fatty acid levels were determined using
a kit from Boehringer Mannheim (Indianapolis, IN). Plasma triglyc-
eride (TG) levels were measured with a TG kit (GPO-Trinder triglyc-
eride kit; Sigma Chemical Co., St. Louis, MO).
 
Islet isolation and culture.
 
Pancreatic islets were isolated accord-
ing to the method of Naber et al. (23) with modifications. They were









 and 95% air (24). The culture me-
dium consisted of RPMI-1640 medium supplemented with 8.0 mM
glucose, 10% fetal bovine serum, 200 U/ml penicillin, 0.2 mg/ml strep-





After 3 days in culture, islets were





of buffer (2 M NaCl/2 mM EDNA/50 mM sodium phosphate, pH

















l of a Triton X-100/methyl alcohol mix-













l of a Triton X-104/methyl alcohol mixture (1:1 vol/vol). TG
content was measured by GPO-Trinder triglyceride kit. In other tis-
sues, TG was measured by the same technique as described previ-
ously (20).




















AdCMV-leptin was infused into lean SL rats,













, baseline plasma leptin levels were elevated in VMHL
Figure 1. Plasma leptin levels in SL and VMHL Sprague Dawley rats 
(A), and ZDF (fa/fa) rats (B) before and 14 days after AdCMV-leptin 





























0.1 ng/nl in SL rats (Fig. 1). In AdCMV-leptin–infused






































Food intake, body weight, and plasma insulin levels.
 
As ex-
pected, the food intake and body weight of VMHL rats in-









While both food intake and body weight were dramatically re-
duced in SL rats infused with AdCMV-leptin, in the AdCMV-
leptin–treated VMHL rats, neither food intake nor body
weight differed from untreated VMHL controls despite a
threefold rise in their previously elevated plasma leptin levels.
The weight of epididymal and retroperitoneal fat in VMHL
rats was significantly greater than that of SL controls and was
not reduced by the increase in hyperleptinemia. Plasma glu-





2.9 mg/dl on day 14, but there was no change in glucose


















were similarly resistant to the effects of the ectopic hyperlep-
tinemia. The lack of a change in either food intake or body
weight in the hyperleptinemic VMHL rats indicated that both
the anorectic and adipocyte-wasting effects of hyperleptinemia
require an intact hypothalamus.


























gal. Hyperleptinemia did not


















U/ml in SL rats.
 
Islet fat content and diabetes.
 









) rats are resistant to the lipopenic action of leptin, the fat
content of their pancreatic islets ranges from 10 to 100 times
normal (25). Islet fat exceeds 25–50 ng/islet at the time that di-
abetes begins, generally between 8–12 wk of age. If the islets of
VMHL rats are also resistant to the lipopenic action of leptin,
an increase in fat content and the appearance of diabetic ab-
normalities should have been evident. However, the islet TG
content of VMHL rats averaged only 19 ng/islet, not signifi-









) rats of similar age and weight contained
over twice as much fat (Fig. 3). This indicates that the islets of
VMHL rats must have been far more responsive to leptin in








) rats and almost as respon-
sive as normal islets. However, whereas the genetic leptin re-








) rats had existed throughout the 7 wk of
their life, the VMHL rats had been leptin-resistant for only 3
wk after their surgery. To determine if more prolonged leptin
resistance would cause accumulation of islet fat and diabetes, a
second group of five VMHL rats was sacrificed 12 wk after
VMH lesioning. The fat content of their islets averaged 21 ng/
islet, which is still not significantly above the SL controls.
Consistent with the lack of increased islet fat content in the
VMHL rats was the absence of overt diabetes during careful
observation up to the age of 20 wk. Although none of the rats
developed fasting hyperglycemia, their intraperitoneal glucose
tolerance test was slightly impaired (Table I). Thus, it ap-
peared that the islets of VMHL rats escape the diabetogenic
consequences of leptin resistance, confirming earlier observa-













) rats, the TG content in islets is paral-
leled by an increase in the TG content of other tissues. In skel-
etal muscle for example, it rose to 13.8 ng/g/wet weight, which





weight (20). This may have been a key factor in their insulin
resistance. For this reason, we measured skeletal muscle TG





Figure 2. Food intake (A), body weight (B), plasma glucose in SL 
and VMHL male Sprague Dawley rats (C), and food intake (D), 
body weight (E), and plasma glucose (F) in ZDF (fa/fa) rats before 
and 14 d after AdCMV-leptin or AdCMV-bgal infusion. Values rep-
resent the mean6SEM of five experiments.
Figure 3. Pancreatic islet triglyceride content of SL and VMHL 
Sprague Dawley rats and ZDF (fa/fa) rats 14 d after AdCMV-leptin 
or AdCMV-bgal infusion and 14 wk after VMHL of Sprague Dawley 
rats. Values represent the mean6SEM of five rats. *P , 0.05 vs. SL 
AdCMV-leptin–infused rats.
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weight, about the same as in normal rats made lipopenic by ad-
enoviral leptin gene transfer (20). This low skeletal muscle fat
may have provided additional protection against diabetes by
increasing insulin sensitivity.
Effect of caloric restriction on in vivo leptin resistance of
VMHL rats. Since leptin resistance can be induced in normal
rodents by increasing their caloric intake (26), we wished to
eliminate any diet-induced impairment of leptin action in
VMHL rats. We therefore placed five hyperphagic VMHL rats
on a diet calorically matched to that of five SL controls and in-
fused them with AdCMV-leptin. This diet matching had re-
duced their caloric intake by 28% prior to the infusion. Their
body weight averaged 32664.5 g 14 d after the infusion, com-
pared with 421619 g in hyperleptinemic rats without dietary
restrictions (P , 0.01); however, this was not less than the
body weight of calorically matched uninfused VMHL rats
(without ectopic hyperleptinemia) and was significantly above
the hyperleptinemic SL rats (260613 g; P , 0.01) (Table II).
Thus, caloric restriction in VHML rats failed to reverse or re-
duce their resistance to the fat-depleting action of ectopic hy-
perleptinemia. In addition, the weight of their epididymal and
retroperitoneal fat depots was no less than that of uninfused
VMHL rats (Fig. 4).
Effects of VMHL on leptin action on islets in vitro. Earlier
studies had shown that leptin directly lowers TG content in
pancreatic islets from normal rats but has no effect in ZDF (fa/
fa) rats with defective leptin receptors. We therefore deter-
mined the in vitro effects of leptin on the TG content of cul-
tured islets from VMHL rats, expecting it to be normal. How-
ever, the lipopenic activity of leptin in VMHL rats was only
50% of SL controls (Fig. 5). To determine if this leptin resis-
tance was due to the ablative procedure itself, or if it was sec-
ondary to the increased food intake that follows VMHL, we
matched the caloric intake of a group of VMHL rats to that of
the SL rats for 2 wk beginning 4 d after the VMH ablation.
This reduced their caloric intake by 28%. This caloric match-
ing resulted in a twofold increase in sensitivity to the lipopenic
action of leptin; the islets were now only 8% less sensitive than
SL controls in terms of lipopenic activity, and this difference
was not significant (NS).
Discussion
This study was designed to determine if obesity produced by
ablation of the VMH causes leptin resistance comparable to
that observed in ZDF (fa/fa) rats, in which a Glu 269 → Pro
mutation in the leptin receptor renders tissues completely re-
sistant to the direct lipopenic effects of recombinant leptin
(16). Whereas the pancreatic islets of wild-type ZDF (1/1)
rats exhibit a . 70% reduction in fat intake when cultured in
the presence of 20 ng/ml of leptin, in islets from ZDF (fa/fa)
rats the elevated TG content is unresponsive to leptin at any
Table I. Postprandial Plasma Glucose (PG), Triglyceride 
(TG), Free Fatty Acids (FFA) Levels, and Glucose Tolerance 
64 d after SL and VMHL of Male Sprague Dawley Rats
SL VMHL
Plasma
PG (mg/dl) 119.564.2 93.863.5*
TG (mg/dl) 90.066.1 175.769.5‡





Data represent the mean6SEM of five experiments. Glucose was in-
jected intraperitoneally in a dose of 2 g/kg/body weight. *P , 0.05 vs.
SL; ‡P , 0.01 vs. SL.
Table II. Plasma Leptin Levels and Body Weight 14 d after AdCMV-Infusion in SL, VMHL Sprague Dawley Rats Fed Ad 
Libitum and VMHL Rats Calorically Matched to SL Control Rats
SL VMHL ad libitum VMHL calorically matched to SL control
Control AdCMV-leptin Control AdCMV-leptin Control AdCMV-leptin
Plasma leptin (ng/ml) 0.9860.06 14.561.5* 7.860.7* 12.062.0‡ 5.560.7* 11.461.5§
Body weight (g) 337611.5 260612.6* 395629.0 421619.4* 31765.2 32664.8
Data represent the mean6SEM of five experiments. *P , 0.01 vs. SL controls; ‡P , 0.05 vs. VMHL ad libitum controls; §P , 0.01 vs. VMHL calori-
cally matched controls.
Figure 4. Wet weight of epididymal and retroperitoneal fat of SL and 
VMHL animals calorically matched to SL Sprague Dawley rats 14 d 
after AdCMV-leptin infusion or without infusion. Values represent 
the mean6SEM of five experiments.
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concentration (16). These findings led us to postulate that lep-
tin acts not only via the hypothalamus but also via direct extra-
hypothalamic effects on tissues that express normal OB-R.
Since it seemed unlikely that a VMH lesion in otherwise nor-
mal rats would reduce either the level of expression or func-
tional activity of OB-R in such target tissues, we expected that
the hyperphagia of VMHL rats would be resistant to the hy-
perleptinemia, but that adipocytes would be rapidly depleted
of fat, as in normal rats. This was not the case. Despite plasma
leptin values threefold above the control VMHL rats, neither
body weight nor the weight of epididymal and retroperitoneal
fat depots were reduced. Finally, although the normal fat con-
tent of their islets suggested that they had been sensitive to
leptin in vivo, the direct in vitro lipopenic action of leptin on is-
lets from VMHL rats was only 50% that of SL controls, indi-
cating a modest level of resistance.
Since increased caloric intake causes leptin resistance (26),
we reasoned that the increased caloric intake of the hyper-
phagic VMHL animals might be inducing peripheral resistance
unrelated to the ablation of the hypothalamic nuclei. To test
this hypothesis, the caloric intake of the hyperphagic VMHL
rats was matched to that of SL controls. This did not reduce ei-
ther body weight or the weight of epididymal or retroperito-
neal fat, but it did improve the lipopenic action of leptin on
isolated islets, bringing it to 92% of SL controls.
In contrast to the complete leptin resistance of ZDF (fa/fa)
rats, in which islet TG content ranges from 10 to 100 times nor-
mal, the TG content in islets of VMHL rats was only minimally
increased, about 10% above normal. In addition, skeletal mus-
cle TG content, which is approximately three times normal in
ZDF (fa/fa) rats, was subnormal in VMHL rats. This could be
construed as evidence of sensitivity to leptin’s lipopenic action
in vivo. Since the islet cell dysfunction, insulin resistance, and
diabetes of ZDF (fa/fa) rats has been attributed to the accumu-
lation of tissue fat (25), it was of interest to examine VMHL
rats for evidence of diabetes. In VMHL rats, there was no ele-
vation in fasting glucose levels at any time during 90 d of ob-
servation, and their postprandial blood glucose levels, though
normal, were lower than in the SL controls (Fig. 2 C). How-
ever, the intraperitoneal glucose tolerance test carried out 64 d
after lesioning revealed high levels at 1 and 2 h (Table I),
which may reflect modest insulin resistance and account for
the higher insulin levels of the VMHL rats.
The leptin resistance of VMHL rats is manifested by intense
hyperphagia and substantial weight gain despite hyperleptine-
mia. A further increase in hyperleptinemia caused by ectopic
leptin expression does not reduce food intake, body weight
gain, or weight of fat depots. When the food intake of AdCMV-
leptin–infused VMHL rats is calorically matched to SL controls
to eliminate leptin resistance secondary to high caloric intake,
there is still no apparent sensitivity to the ectopic hyperleptine-
mia in the form of a reduction in body weight or weight of fat
depots. Thus, the fat-depleting effect of hyperleptinemia is ei-
ther mediated by the VMH through direct neuronal signaling
pathways or via a hypothalamic factor that directly or indirectly
renders adipocytes sensitive to direct action of leptin.
Islets isolated from VMHL rats on an unrestricted diet were
somewhat resistant to the lipopenic action of recombinant lep-
tin; however, when the caloric intake of the VMHL rats was re-
duced to that of SL controls, there was marked improvement in
their sensitivity to the lipopenic action of leptin. This suggests
that the peripheral resistance of islets to leptin may in part be
the result of the high caloric intake rather than to the loss of
central regulatory factors originating from the VMH (27).
Clearly, the VMHL model of obesity differs strikingly from
the fa/fa ZDF model. Although the hyperphagia is similar in
the two, plasma and tissue lipids are considerably higher in the
ZDF rats. Since food intake averages about 30 g/d in both
groups of rats, it is likely that these differences reflect altered
metabolism of the ingested nutrients in the ZDF rats. We have
already established that lipogenesis is markedly increased in
their tissues (25), and more recently, we have found that ex-
pression of the enzymes of lipogenesis such as acetyl CoA car-
boxylase and fatty acid synthetase (Zhou, Y.-T., Y. Lee, K.
Koyama, T. Ferguson, and R.H. Unger, unpublished data) is
greatly increased. Since the increased lipogenesis can be re-
versed by expressing the wild-type leptin receptor in their tissues
(28), we speculate that in VMHL rats, overexpression of lipo-
genic enzymes and thus their lipogenic capacity is constrained by
a direct action of the hyperleptinemia on OB-R–expressing tis-
sues. In ZDF rats, by contrast, these tissues are completely un-
responsive to the hyperleptinemia, and the lack of any direct
leptin action results in a much greater lipogenic capacity.
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